Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation
Top Cited Papers
- 29 January 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 139 (5), 604-616
- https://doi.org/10.1161/circulationaha.118.036768
Abstract
Background: Despite recommendations in the guidelines and consensus documents, there has been no randomized controlled trial evaluating oral anticoagulation (OAC) alone without antiplatelet therapy (APT) in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) beyond 1 year after coronary stenting. Methods: This study was a prospective, multicenter, open-label, non-inferiority trial, comparing OAC alone to combined OAC and single APT among AF patients beyond 1 year after stenting in a 1:1 randomization fashion. The primary endpoint was a composite of all-cause death, myocardial infarction (MI), stroke, or systemic embolism. The major secondary endpoint was a composite of primary endpoint or major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) classification. Although the trial was designed to enroll 2,000 patients during 12 months, enrollment was prematurely terminated after enrolling 696 patients in 38 months. Results: Mean age was 75.0±7.6 years, and 85.2% of patients were men. OAC was warfarin in 75.2% and direct oral anticoagulants in 24.8% of patients. The mean CHADS2 score was 2.5±1.2. During a median follow-up interval of 2.5 years, the primary endpoint occurred in 54 patients (15.7%) in the OAC alone group and in 47 patients (13.6%) in the combined OAC and APT group (HR, 1.16; 95% confidence interval [CI], 0.79-1.72; P=0.20 for non-inferiority; P=0.45 for superiority). The major secondary endpoint occurred in 67 patients (19.5%) in the OAC alone group and in 67 patients (19.4%) in the combined OAC and APT group (HR, 0.99; 95% CI, 0.71-1.39; P=0.016 for non-inferiority; P=0.96 for superiority). MI occurred in 8 (2.3%) and 4 (1.2%) patients, while stroke or systemic embolism occurred in 13 (3.8%) and 19 (5.5%) patients, respectively. Major bleeding occurred in 27 (7.8%) and 36 (10.4%) patients, respectively. Conclusions: This randomized trial did not establish non-inferiority of OAC alone to combined OAC and APT in patients with AF and stable CAD beyond 1 year after stenting. Because patient enrollment was prematurely terminated, the study was underpowered and inconclusive. Future larger studies are required to establish the optimal antithrombotic regimen in this population. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01962545.This publication has 52 references indexed in Scilit:
- Dabigatran Versus WarfarinStroke, 2013
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- Very Late Stent Thrombosis and Late Target Lesion Revascularization After Sirolimus-Eluting Stent ImplantationCirculation, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Newly Identified Events in the RE-LY TrialThe New England Journal of Medicine, 2010
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Low Diagnostic Yield of Elective Coronary AngiographyThe New England Journal of Medicine, 2010
- Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trialsAmerican Heart Journal, 2006
- Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial FibrillationStroke, 2000
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996